TC
Tarsem Chand Kansal
About Tarsem Chand Kansal
Data last updated:
Tarsem Chand Kansal was a Director at Systole Remedies Private Limited (2005–2017), Director at Scholls Pharma And Chemicals Private Limited (from 2002) and Director at Elicon Biotech Private Limited (from 2017). The companies operate in Pharma.
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Systole Remedies Private Limited U24230DL2005PTC191854 | Director | 24 Jan 2005 | 2005 | ₹59.68 Cr (FY 2025) | Active |
 Scholls Pharma And Chemicals Private Limited U24231HR2002PTC034855 | Director | 02 Apr 2002 | 2002 | Strike Off | |
| Elicon Biotech Private Limited U24304HR2017PTC070969 | Director | 29 Sep 2017 | 2017 | Strike Off |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Tarsem Chand Kansal
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tarsem Chand Kansal
Tarsem Chand Kansal was first appointed on 02 Apr 2002 as Director at Scholls Pharma And Chemicals Private Limited. The most recent appointment on record is 29 Sep 2017 at Elicon Biotech Private Limited.
Tarsem Chand Kansal held 3 earlier board appointments: Systole Remedies Private Limited (Director, 24 Jan 2005 to 22 Nov 2017); Scholls Pharma And Chemicals Private Limited (Director, from 02 Apr 2002); Elicon Biotech Private Limited (Director, from 29 Sep 2017).